Cancer Immunotherapy Market: Current Analysis and Forecast 2021-2027

$3500$6860

Emphasis on Therapy Type (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines, and Others), Application (Lung cancer, Breast cancer, Colorectal cancer, Melanoma, Prostate cancer, Head and neck cancer, Others), End-User (Cancer Specialty/Research Centers, Hospitals & Clinics), and Region/Country

Pages:

261

Table:

96

Figure:

160

Report ID:

UMHE21209

Geography:

Clear
  Get a Free Sample
SKU: UMHE21209 Category:
Report Description
Table of content
Research Methodology

Report Description

Conventional cancer treatments are still the most practiced and the most canonical therapies of today`s medical anti-cancer strategies. They comprise surgery, chemotherapy, and radiation therapy, while cancer immunotherapy is emerging as the new approach that is further being increasingly accepted and has only recently been innovated and approved. In early 2018, approximately 32 monoclonal antibodies were approved by the FDA or EMA for cancer immunotherapy for a cancer indication and medical purpose. The surging cancer incidence and rising geriatric population is anticipated to boost the market growth. In 2020, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) will be diagnosed worldwide, with almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer). Female breast cancer has surpassed lung cancer as the most diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancers.

According to a study titled as “Estimation of the Percentage of US Patients with Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs” conducted in 2019 by Alyson Haslam and Vinay Prasad, the estimated percentage of eligible cancer patients in the United States for checkpoint inhibitor drugs was 1.54% in 2011 and increased to an estimated 26.86% by 2015 and 43.63% in 2018. Furthermore, NSCLC (21.48%), hepatocellular carcinoma (4.95%), and SCLC were the diseases that contributed the most to the eligibility calculation (3.79%). In 2016, immunotherapy treatments captured 33% of spending on oncology drugs, despite accounting for just 9% of FDA-approved oncology drugs. All the large oncology drug companies are building robust immunotherapy pipelines, driving increased M&A and investor interest. Several cancer immunotherapies such as monoclonal antibodies have the diverse set of clinically relevant mechanisms of action like directly targeting tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. During the outbreak of COVID-19, several cancer patients worldwide had experienced long-lasting city lockdown and delay of immunotherapies. For instance, in China treatment showed that the delay of three to four months might have mild, if any, influence on the efficacy of immunotherapy for patients with well-controlled disease.

Timeline of FDA-approved Cancer Immunotherapies

AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, and Pfizer are some of the prominent players operating in the global Cancer Immunotherapy market. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.

Insights Presented in the Report

“Amongst therapy, monoclonal antibodies segment holds the major share”

Based on the therapy type, the market is fragmented into monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others. The monoclonal antibodies segment dominated the market with a share of 37.3% in 2020 and is expected to maintain its dominance during the forecast period owing to the diverse set of clinically relevant mechanisms of action.

“Amongst application, breast cancer is anticipated to grow at the highest CAGR during the analyzed period”

Further based on application, the market is fragmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, other cancer applications. In 2020, lung cancer accounted for a maximum market revenue share of 25.5% and is expected to remain dominant during the analyzed period. However, the breast segment is anticipated to grow at the highest CAGR over the forecast period and reach market evaluation of USD 36.10 million by the end of the forecast year. Breast cancer accounts for 1 in 4 cancer cases and 1 in 6 in cancer mortality.

Amongst end-user, cancer specialty/research centers segment holds the major share”

Based on the end-user type, the market is fragmented into Cancer Specialty/Research Centers and hospitals and clinics. The cancer specialty/research centers dominated the market in 2020 with revenue of USD 55.43 billion and are anticipated to maintain their dominance during the analyzed period. Furthermore, the segment is also expected to grow at the highest CAGR during the period.

“North America signifies one of the largest markets of Cancer Immunotherapy Market”

For a better understanding of the market dynamics of the Cancer Immunotherapy market, a detailed analysis was conducted for different regions across the globe including North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of USD 37.56 billion in 2020. In America, nearly 1.9 million new cancer cases are expected to be diagnosed in 2021. Approximately 608,570 Americans are expected to die of cancer in 2021, which translates to about 1,670 deaths per day. Cancer is the second most common cause of death in the US, exceeded only by heart disease.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts
  • The report presents a quick review of overall industry performance at one glance
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
  • The study comprehensively covers the market across different segments
  • Deep dive regional level analysis of the industry

Customization Options:

The Cancer Immunotherapy Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

You can also purchase parts of this report. Do you want to check out a section wise
price list?

  1.1Market Definitions
  1.2Objective of the Study
  1.3Limitation
  1.4Stake Holders
  1.5Currency Used in Report
  1.6Scope of the Global Cancer Immunotherapy Market Study

 

  2.1Research Methodology for the Global Cancer Immunotherapy Market
   2.1.1Main Objective of the Global Cancer Immunotherapy Market

 

  8.1Monoclonal Antibodies
  8.2Vaccines 
  8.3Checkpoint Inhibitors
  8.4Cell Therapies
  8.5Immune System Modulators
  8.6Adoptive Cell Transfer
  8.7Cytokines
  8.8Others

 

  9.1Lung Cancer
  9.2Breast Cancer
  9.3Colorectal Cancer
  9.4Melanoma
  9.5Prostate Cancer
  9.6Head and Neck Cancer
  9.7Other Cancer Applications

 

  10.1Cancer Specialty/Research Centers
  10.2Hospitals & Clinics

 

  11.1North America Cancer Immunotherapy Market 
   11.1.1United States
   11.1.2Canada
  11.2Europe Cancer Immunotherapy Market 
   11.2.1Germany
   11.2.2France
   11.2.3United Kingdom
   11.2.4Italy
   11.2.5Spain
   11.2.6Rest of Europe
  11.3Asia Pacific Cancer Immunotherapy Market
   11.3.1China
   11.3.2Japan
   11.3.3India
   11.3.4Australia
   11.3.5Rest of Asia Pacific
  11.4Rest of World Cancer Immunotherapy Market 

 

  12.1Market Drivers
  12.2Market Challenges
  12.3Impact Analysis
  16.1Demand Side Analysis
  16.2Supply Side Analysis
   16.2.1Top Product Launches
   16.2.2Top Business Partnerships
   16.2.3Top Business Expansions, Investments and Divestitures
   16.2.4Top Merger and Acquisitions
  18.1Porter’s Five Forces Analysis
   18.1.1Bargaining power of Supplier
   18.1.2Bargaining power of Buyer
   18.1.3Industry Rivalry
   18.1.4 Availability of Substitute
   18.1.5Threat of new Entrants
  18.2Competitive Landscape
   18.2.1Company Shares, By Revenue
  19.1AbbVie 
  19.2Amgen 
  19.3AstraZeneca
  19.4bluebird bio
  19.5Bristol-Myers Squibb
  19.6F  Hoffmann-La Roche
  19.7Janssen Biotech
  19.8Merck 
  19.9Novartis 
  19.10Pfizer

Research Methodology

Analyzing the historical market, estimation of the current market, and forecasting the future market of the Global Cancer Immunotherapy Market were the three major steps undertaken to create and analyze the adoption of Cancer Immunotherapy for the different diseases across major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the Cancer Immunotherapy sector. Post assumption and validation of market numbers through primary interviews, we employed a top-down approach to forecast the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments the industry pertains to. Detailed methodology is explained below:

Analysis of Historical Market Size

Step 1: In-Depth Study of Secondary Sources:

Detailed secondary study was conducted to obtain the historical market size of the Cancer Immunotherapy through company internal sources such as annual report & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.

Step 2: Market Segmentation:

After obtaining the historical market size of the Cancer Immunotherapy market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments for major regions. Major segments included in the report are therapy, application, and end-user. Further country-level analyses were conducted to evaluate the overall adoption of Cancer Immunotherapy in every region.

Step 3: Factor Analysis:

After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of Cancer Immunotherapy. Further, we conducted factor analysis using dependent and independent variables such as increasing cancer incidence and growing geriatric population. A thorough analysis was conducted for demand and supply-side scenario considering top partnerships, merger and acquisition, business expansion, and product launches in the Cancer Immunotherapy industry across the globe.

Current Market Size Estimate & Forecast

Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the Cancer Immunotherapy market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.

Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e. top-down/bottom-up approach was applied to arrive at the market forecast about 2027 for different segments and subsegments across the major markets globally. The research methodology adopted to estimate the market size encompasses:

  • The industry’s market size, in terms of value (USD) and the adoption rate of Cancer Immunotherapy across the major markets domestically
  • All percentage shares, splits, and breakdowns of market segments and sub-segments
  • Key players in the Cancer Immunotherapy market in terms of services offered. Also, the growth strategies adopted by these players to compete in the fast-growing market

Market Size and Share Validation

Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, and Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.

Split of Primary Participants in Different Regions

Market Engineering

Data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers of each segment and sub-segment of the Cancer Immunotherapy market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of therapy, application, and end-user of the Cancer Immunotherapy market.

Main Objective of the Cancer Immunotherapy Market Study

The current & future market trends of Cancer Immunotherapy were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments from the qualitative and quantitative analysis performed in the study. Current and future market trends were determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit as a first-mover advantage. Other quantitative goals of the studies include:

  • Analyze the current and forecast market size of Cancer Immunotherapy in terms of value (USD). Also, analyze the current and forecast market size of different segments and sub-segments
  • Segments in the study include areas of therapy, application and end-user
  • Define and analysis of the regulatory framework for the Cancer Immunotherapy industry
  • Analyze the value chain involved with the presence of various intermediaries, along with analyzing customer and competitor behaviors of the industry
  • Analyze the current and forecast market size of the Cancer Immunotherapy market for the major region
  • Major regions studied in the report include North America (the United States and Canada), Europe (Germany, France, Italy, Spain, and United Kingdom), Asia-Pacific (China, Japan, India and Australia), and Rest of the World
  • Company profiles of the Cancer Immunotherapy market and the growth strategies adopted by the market players to sustain in the fast-growing market
  • Deep dive regional level analysis of the industry